X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 12.1 36.2 33.3% View Chart
P/BV x 3.2 3.0 105.8% View Chart
Dividend Yield % 0.4 0.8 46.9%  

Financials

 GLENMARK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
GLENMARK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9932,095 47.4%   
Low Rs7291,025 71.2%   
Sales per share (Unadj.) Rs325.5492.8 66.1%  
Earnings per share (Unadj.) Rs39.372.6 54.2%  
Cash flow per share (Unadj.) Rs48.794.7 51.4%  
Dividends per share (Unadj.) Rs2.0021.00 9.5%  
Dividend yield (eoy) %0.21.3 17.3%  
Book value per share (Unadj.) Rs159.2862.5 18.5%  
Shares outstanding (eoy) m282.17172.56 163.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.2 83.6%   
Avg P/E ratio x21.921.5 101.9%  
P/CF ratio (eoy) x17.716.5 107.4%  
Price / Book Value ratio x5.41.8 299.0%  
Dividend payout %5.128.9 17.6%   
Avg Mkt Cap Rs m242,991269,194 90.3%   
No. of employees `00013.04.0 323.1%   
Total wages/salary Rs m16,40817,939 91.5%   
Avg. sales/employee Rs Th7,083.921,190.3 33.4%   
Avg. wages/employee Rs Th1,265.44,470.1 28.3%   
Avg. net profit/employee Rs Th855.13,120.0 27.4%   
INCOME DATA
Net Sales Rs m91,85785,037 108.0%  
Other income Rs m3742,338 16.0%   
Total revenues Rs m92,23087,374 105.6%   
Gross profit Rs m20,36734,991 58.2%  
Depreciation Rs m2,6443,817 69.3%   
Interest Rs m2,37320,310 11.7%   
Profit before tax Rs m15,72413,202 119.1%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-100 813.6%   
Tax Rs m3,8272,281 167.8%   
Profit after tax Rs m11,08812,520 88.6%  
Gross profit margin %22.241.1 53.9%  
Effective tax rate %24.317.3 140.9%   
Net profit margin %12.114.7 82.0%  
BALANCE SHEET DATA
Current assets Rs m68,74687,590 78.5%   
Current liabilities Rs m27,027185,578 14.6%   
Net working cap to sales %45.4-115.2 -39.4%  
Current ratio x2.50.5 538.9%  
Inventory Days Days8531 273.9%  
Debtors Days Days9648 200.9%  
Net fixed assets Rs m24,132108,523 22.2%   
Share capital Rs m282345 81.8%   
"Free" reserves Rs m44,643148,481 30.1%   
Net worth Rs m44,925148,826 30.2%   
Long term debt Rs m45,363144,957 31.3%   
Total assets Rs m117,639482,394 24.4%  
Interest coverage x7.61.7 462.1%   
Debt to equity ratio x1.01.0 103.7%  
Sales to assets ratio x0.80.2 443.0%   
Return on assets %11.46.8 168.1%  
Return on equity %24.78.4 293.4%  
Return on capital %19.112.0 160.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15215,001 374.3%   
Fx outflow Rs m8,0845,150 157.0%   
Net fx Rs m48,0689,851 487.9%   
CASH FLOW
From Operations Rs m6,574-100,393 -6.5%  
From Investments Rs m-7,124-24,202 29.4%  
From Financial Activity Rs m5,432135,705 4.0%  
Net Cashflow Rs m1,99211,110 17.9%  

Share Holding

Indian Promoters % 48.3 52.9 91.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.0 172.5%  
FIIs % 34.4 26.6 129.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   56,727 93,274 60.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 22, 2018 12:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS